The trend of susceptibilities to amphotericin B and fluconazole of Candida species from 1999 to 2002 in Taiwan

BMC Infectious Diseases

Volumn 5, Issue , 2005, Pages

  Yang, Yun Liang ^a   Li, Shu Ying ^b   Cheng, Hsiao Hsu ^c   Lo, Hsiu Jung ^c  

^a NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

^b CENTER FOR DISEASE CONTROL   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; ANTIFUNGAL AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SENSITIVITY; FUNGAL STRAIN; FUNGUS GROWTH; FUNGUS ISOLATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; SPECIES DIVERSITY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TAIWAN; ANTIFUNGAL RESISTANCE; DRUG EFFECT; EVOLUTION; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; PHYSIOLOGY;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; BIOLOGICAL EVOLUTION; CANDIDA; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS; TAIWAN;

EID: 27844521823     PISSN: 14712334     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-5-99     Document Type: Article

References (27)

1. Hung CC, Chen YC, Chang SC, Luh KT, Hsieh WC: Nosocomial candidemia in a university hospital in Taiwan. J Formos Med Assoc 1996, 95: 19-28.
2. Chen YC, Chang SC, Sun CC, Yang LS, Hsieh WC, Luh KT: Secular trends in the epidemiology of nosocomial fungal infections at a teaching hospital in Taiwan, 1981 to 1993. Infect Control Hosp Epidemiol 1997, 18: 369-375.
3. Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel RP: National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic. Diagn Microbiol Infect Dis 1998, 30: 121-129.
4. Beek-Sague C, Jarvis WR: Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J Infect Dis 1993, 167: 1247-1251.
5. Leleu G, Aegerter P, Guidet B: Systemic candidiasis in intensive care units: a multicenter, matched-cohort study. J Crit Care 2002, 17: 168-175.
6. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP: Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med 1988, 148: 2642-2645.
7. Tortorano AM, Caspani L, Rigoni AL, Biraghi E, Sicignano A, Viviani MA: Candidosis in the intensive care unit: a 20-year survey. J Hosp Infect 2004, 57: 8-13.
8. Lo HJ, Ho AH, Ho M: Factors accounting for mis-identification of Candida species. J Microbiol Immunol Infect 2001, 34: 171-177.
9. Yang YL, Ho YA, Cheng HH, Ho M, Lo HJ: Susceptibilities of Candida species to amphotericin B and fluconazole: the emergence of fluconazole resistance in Candida tropicalis. Infect Control Hosp Epidemiol 2004, 25: 60-64.
10. Hadfield TL, Smith MB, Winn RE, Rinaldi MG, Guerra C: Mycoses caused by Candida lusitaniae. Rev Infect Dis 1987, 9: 1006-1012.
11. Akova M, Akalin HE, Uzun O, Gur D: Emergence of Candida krusei infections after therapy of oropharyngeal candidiasis with fluconazole. Eur J Clin Microbiol Infect Dis 1991, 10: 598-599.
12. Orozco AS, Higginbotham LM, Hitchcock CA, Parkinson T, Falconer D, Ibrahim AS et al.: Mechanism of fluconazole resistance in Candida krusei. Antimicrob Agents Chemother 1998, 42: 2645-2649.
13. Yang YL, Cheng HH, Lo HJ: In vitro activity of voriconazole against Candida species isolated in Taiwan. Int J Antimicrob Agents 2004, 24: 294-296.
14. Piemonte P, Conte G, Flores C, Barahona O, Araos D, Alfaro J et al.: Emergency of fluconazole-resistant infections by Candida krusei and Candida glabrata in neutropenic patients. Rev Med Chil 1996, 124: 1149.
15. Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ: Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001. J Clin Microbiol 2003, 41: 1440-1446.
16. Hsueh PR, Lau YJ, Chuang YC, Wan JH, Huang WK, Shyr JM et al.: Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003. Antimicrob Agents Chemother 2005, 49: 512-517.
17. Pfaller MA, Messer SA, Boyken L, Hollis RJ, Rice C, Tendolkar S et al.: In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis 2004, 48: 201-205.
18. Pfaller MA, Diekema DJ, Jones RN, Sader HS, Fluit AC, Hollis RJ et al.: International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 2001, 39: 3254-3259.
19. Yang YL, Li SY, Cheng HH, Lo HJ: Susceptibilities to amphotericin B and fluconazole of Candida species in TSARY 2002. Diagn Microbiol Infect Dis 2005, 51: 179-183.
20. Larone DH: Laboratory Procedures. In Medically Important Fungi: A Guide to Identification. New York: ASM Press; 1995:209-224.
21. Sullivan D, Coleman D: Candida dubliniensis: characteristics and identification. J Clin Microbiol 1998, 36:329-334.
22. Clinical and Laboratory Standards Institute (formly, NCCLS): Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. M27 A, Wayne, PA 1997.
23. Pfaller MA, Espinel-Ingroff A, Jones RN: Clinical evaluation of the Sensititre VeastOne colorimetric antifungal plate for antifungal susceptibility testing of the new triazoles voriconazole, posaconazole, and ravuconazole. J Clin Microbiol 2004, 42: 4577-4580.
24. Yang YL, Cheng HH, Ho YA, Hsiao CF, Lo HJ: Fluconazole resistance rate of Candida species from different regions and hospital types in Taiwan. J Microbiol Immunol Infect 2003, 36: 187-191.
25. Bennett JE, Izumikawa K, Marr KA: Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis. Antimicrob Agents Chemother 2004, 48: 1773-1777.
26. Sanglard D, Ischer F, Calabrese D, Majcherczyk PA, Bille J: The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents. Antimicrob Agents Chemother 1999, 43: 2753-2765.
27. Sanguinetti M, Posteraro B, Fiori B, Ranno S, Torelli R, Fadda G: Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob Agents Chemother 2005, 49: 668-679.